Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06259552 · ClinicalTrials.gov registry record · Phase 1
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
A Phase 1 study of Solid Tumor and HNSCC, sponsored by SparX Biotech(Jiangsu) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 232
- Enrollment target
- 4
- Study locations
NCT06259552: Recruiting Phase 1 study of Solid Tumor and HNSCC, sponsored by SparX Biotech(Jiangsu) Co..
NCT06259552 is a Phase 1 study of Solid Tumor and HNSCC that is actively recruiting participants, run by SparX Biotech(Jiangsu) Co.. The registered enrollment target is 232 participants, roughly in line with the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target. The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06259552, a Phase 1 study of Solid Tumor and HNSCC, is actively recruiting participants, sponsored by SparX Biotech(Jiangsu) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 232 participants
- Enrollment target
- 4
- Study locations
Study Summary
Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.
Primary Outcome
A DLT is defined as the clinically significant TRAE(treatment-related adverse events) or abnormal laboratory values assessment during the first 21 days of Cycle 1 and excludes events that are deemed clearly related to underlying disease, progression, or intercurrent illness.
Conditions Studied
Interventions
- BIOLOGICAL SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody
Study Locations (4)
Arizona
- Mayo Clinic Arizona - Phoenix
- HonorHealth Research and Innovation Institute - Scottsdale
Florida
- Mayo Clinic Florida - Jacksonville
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2024-03-20 |
| Est. Completion | 2027-09 |
| Phase | Phase 1 |
What NCT06259552 shows while recruiting
NCT06259552 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target.
The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody is the first listed.
NCT06259552 reports a single indexed study location in Arizona, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06259552 about?
NCT06259552 is a clinical study titled "A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors". Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.
What is the current status of trial NCT06259552?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 232 participants. The study started on 2024-03-20. Estimated completion is 2027-09.
What conditions does trial NCT06259552 study?
This clinical trial studies the following conditions: Solid Tumor, HNSCC, CRC, RCC.
What interventions are being tested in trial NCT06259552?
The interventions under investigation include: SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT06259552?
This trial is sponsored by SparX Biotech(Jiangsu) Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06259552 being conducted?
This trial has 4 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06259552's enrollment target sits among peer trials
232 30th of 196 higher than 167 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI